NuSirt Biopharma, Inc. has developed a breakthrough technology platform that combines natural compounds with various pharmaceutical agents.
The company has protected the discovery and application of this broad based technology platform through an extensive IP portfolio that includes thirteen issued or allowed to date with corresponding patents pending globally. NuSirt has successfully conducted multiple clinical studies that have validated its discovery and demonstrated the value of its intellectual property.
Learn MoreNS-WM-01 enrollment completed
11th Annual Diabetes Summit, April 10-11, Boston, MA
Joe Cook, Jr. to present in the “Funding and Commercialization” Session
Michael Zemel, PhD to present, “Clinical Utility of Energy-Sensing Targets for Diabetes & Metabolic Syndrome” in the “What’s New in Type 2 Diabetes Session”
EASL abstract accepted, presentation date, April 12, 2018 Paris, France
See All News
3835 Cleghorn Avenue, Suite 200
Nashville, TN 37215
615-810-8191